Composition of Certain Financial Statement Captions (Tables)

12 Months Ended

Dec. 31, 2017

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Composition of Certain Financial Statement Captions

	For the years ended December 31,
(In thousands)	2017			2016
Accounts receivable, net
Accounts receivable	$	166,962		$	221,955
Less: allowance for doubtful accounts	(1,446		)	(1,671		)
	$	165,516		$	220,284
Inventories, net
Consumable supplies	$	21,546		$	23,448
Finished products	21,012			16,143
Work in-process	5,873			3,896
Raw materials	7,467			4,686
Less: inventory reserve	(6,565		)	(945		)
	$	49,333		$	47,228
Other current assets and prepaid expenses
Other receivables	$	3,398		$	13,021
Taxes recoverable	18,138			16,187
Prepaid supplies	8,207			6,952
Prepaid insurance	3,532			3,688
Other	9,238			7,508
	$	42,513		$	47,356
Property, plant and equipment, net:
Machinery, medical and other equipment	$	112,961		$	100,100
Leasehold improvements	34,121			30,122
Furniture and fixtures	11,540			11,247
Automobiles and aircraft	11,137			13,342
Software	12,469			10,990
Building	8,227			5,696
Land	2,552			2,264
Construction in process	39,397			5,848
Less: accumulated depreciation	(85,847		)	(56,778		)
	$	146,557		$	122,831
Intangible assets, net:
Customer relationships	$	448,345		$	443,560
Technologies	340,921			340,397
Trade names	50,553			50,442
Covenants not to compete	16,372			16,348
Licenses	10,305			23,506
Product registrations	10,475			7,641
Other	5,799			5,289
Less:  accumulated amortization	(198,935		)	(123,207		)
	$	683,835		$	763,976
Accrued expenses:
Contract liabilities	$	56,883		$	50,158
Employee benefits	50,377			43,792
Taxes payable	4,609			4,430
Contingent consideration	11,750			259

	For the years ended December 31,
(In thousands)	2017		2016
Clinical trials	12,191		5,935
Capital leases short-term	3,399		3,025
Milestone payment	4,868		4,865
Professional fees	2,355		4,035
Other	79,364		58,180
	$	225,796	$	174,679
Other long-term liabilities:
Contract liabilities	$	95,450	$	157,667
Line of credit	104,152		38,809
Contingent consideration	29,603		44,817
Capital leases long-term	7,786		7,216
Mortgages and other debts payable	1,567		717
Other	17,857		21,908
	$	256,415	$	271,134

Summary of Fair Values Assigned to Major Intangible Asset Classes

The following table summarizes the fair values assigned to our major intangible asset classes upon each acquisition:

(In thousands)	Technologies		In-process research and development		Customer relationships		Product registrations		Covenants not to compete		Trade names		Other		Total identified intangible assets		Goodwill
BioReference	$	100,600	$	—	$	389,800	$	—	$	7,750	$	47,100	$	—	$	545,250	$	401,821
CURNA	—		10,000		—		—		—		—		290		10,290		4,827
EirGen	—		560		34,155		—		—		—		3,919		38,634		83,373
FineTech	2,700		—		14,200		—		1,500		400		—		18,800		11,623
OPKO Biologics	—		590,200		—		—		—		—		—		590,200		139,784
OPKO Chile	—		—		3,945		5,829		—		1,032		—		10,806		5,441
OPKO Diagnostics	44,400		—		—		—		—		—		—		44,400		17,977
OPKO Health Europe	3,017		1,459		436		2,930		187		349		—		8,378		8,062
OPKO Lab	1,370		—		3,860		—		6,900		1,830		70		14,030		29,629
OPKO Renal	—		191,530		—		—		—		—		210		191,740		2,411
Transition Therapeutics	—		41,000		—		—		—		—		—		41,000		3,453
Weighted average amortization period	8-12 years		Indefinite		6-20 years		9 years		5 years		4-5 years		3-10 years				Indefinite

Summary of Valuation Allowance

The following table reflects the changes in the allowance for doubtful accounts, provision for inventory reserve and tax valuation allowance accounts:

(In thousands)	Beginning balance			Charged to expense		Written-off		Charged to other		Ending balance
2017
Allowance for doubtful accounts	$	(1,671	)	(891	)	1,063		53		$	(1,446	)
Inventory reserve	$	(945	)	(5,390	)	(230	)	—		$	(6,565	)
Tax valuation allowance	$	(55,415	)	(82,358	)	—		(4,289	)	$	(142,062	)
2016
Allowance for doubtful accounts	$	(1,946	)	(932	)	1,110		97		$	(1,671	)
Inventory reserve	$	(1,051	)	(20	)	296		(170	)	$	(945	)
Tax valuation allowance	$	(42,147	)	7,726		—		(20,994	)	$	(55,415	)

Schedule of Goodwill

The following table summarizes the changes in Goodwill during the years ended December 31, 2017 and 2016.

	2017											2016
(In thousands)	Balance at January 1		Purchase Accounting Adj			Foreign exchange and other			Balance at December 31st			Balance at January 1			Purchase accounting adjustments				Foreign exchange				Balance at December 31
Pharmaceuticals
CURNA	$	4,827			$	—		$	4,827		$	4,827		$	—			$	—			$	4,827
EirGen	78,358					10,868			89,226			81,139			—				(2,781		)		78,358
FineTech	11,698					—			11,698			11,698			—				—				11,698
OPKO Biologics	139,784					—			139,784			139,784			—				—				139,784
OPKO Chile	4,785					418			5,203			4,517			—				268				4,785
OPKO Health Europe	6,936					962			7,898			7,191			—				(255		)		6,936
OPKO Renal	2,069					—			2,069			2,069			—				—				2,069
Transition Therapeutics	3,360					248			3,608			—			3,453				(93		)		3,360
Diagnostics
BioReference	401,821					—			401,821			441,158			(39,337		)		—				401,821
OPKO Diagnostics	17,977					—			17,977			17,977			—				—				17,977
OPKO Lab	32,988					—			32,988			32,988			—				—				32,988
	$	704,603	$	—		$	12,496		$	717,099		$	743,348		$	(35,884	)		$	(2,861	)		$	704,603